Phase 3 Recruiting Network
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …
Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
- Natalie Warren Bryant Cancer Center at Saint Francis — Tulsa, Oklahoma
Phase 3 Recruiting Industry
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AM…
Sponsor: Daiichi Sankyo
NCT ID: NCT06578247
Sites in Oklahoma: - Peggy & Charles Stephenson Oklahoma Cancer Ctr — Oklahoma City, Oklahoma
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Oklahoma: - Oklahoma Cancer Specialists and Research Institute /ID# 267643 — Tulsa, Oklahoma
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
- Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
NCT ID: NCT03331198
Sites in Oklahoma: - University of Oklahoma Health Sciences Center (Stephenson Cancer Center) — Oklahoma City, Oklahoma
- University of Oklahoma Peggy and Charles Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 2 Recruiting Academic/Other
This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or m…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06390319
Sites in Oklahoma: - Saint Francis Children's Hospital — Tulsa, Oklahoma
Phase 1 Recruiting NIH
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemi…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05886049
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Academic/Other
This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, mole…
Sponsor: University of Oklahoma
NCT ID: NCT03633955
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Oklahoma: - University of Oklahoma Health Science Center — Oklahoma City, Oklahoma
Recruiting Network
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hyd…
Sponsor: Children's Oncology Group
NCT ID: NCT01790152
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Recruiting Industry
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
Sponsor: Blueprint Medicines Corporation
NCT ID: NCT07143669
Sites in Oklahoma: - Allergy, Asthma & Clinical Research Center — Oklahoma City, Oklahoma
Recruiting Industry
This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population
Sponsor: Fresenius Kabi
NCT ID: NCT06274788
Sites in Oklahoma: - Board of Regents of the University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 4 Recruiting Academic/Other
The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the AL…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06289673
Sites in Oklahoma: - Saint Francis Children's Hospital — Tulsa, Oklahoma